IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis

GSVA: gene set variation analysis for microarray and RNA-Seq data

Sonja Hänzelmann, Robert Castelo, Justin Guinney · BMC Bioinformatics · 2013 · 16.5K citations · Full text

Life Sciences, Bioinformatics, Molecular Biology +17

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Dermatology, Immunology +14

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Dominique Baeten, Joachim Sieper, Jürgen Braun et al. · New England Journal of Medicine · 2015 · 1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 850 citations

Life Sciences, Immunology, Pharmacotherapy +15

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways

Kristine Nograles, Lisa C. Zaba, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2008 · 799 citations · Full text

Medicine, Dermatology, Immunology +17